2
|
· |
our expectation that, for the foreseeable future, a significant portion of our revenues will be derived from sales of Panorama; |
|
· |
our ability to increase demand for Panorama, expand geographically, and obtain favorable coverage and reimbursement determinations from third-party payers; |
|
· |
our reliance on our partners to market and offer Panorama in the United States and in international markets; |
|
· |
our expectation that Panorama will be adopted for broader use in average-risk pregnancies and for the screening of microdeletions and that third-party payer reimbursement will be available for these applications; |
|
· |
developments or disputes concerning our intellectual property or other proprietary rights; |
|
· |
our ability to successfully expand our product offerings to include cancer-related and other diagnostic tests; |
|
· |
competition in the markets we serve; |
|
· |
our expectations of the reliability, accuracy, and performance of Panorama; |
|
· |
our expectations of the benefits to patients, providers, and payers of Panorama; |
|
· |
our reliance on collaborators such as medical institutions, contract laboratories, laboratory partners, and other third parties; |
|
· |
our ability to operate our laboratory facility and meet expected demand; |
|
· |
our reliance on a limited number of suppliers, including sole source suppliers, which may impact the availability of replacement laboratory instruments and materials; |
|
· |
our expectations of the rate of adoption of Panorama and of any of our future tests by laboratories, clinics, clinicians, payers, and patients; |
3
|
· |
our ability to publish clinical data in peer-reviewed medical publications regarding Panorama and any of our future tests; |
|
· |
our ability to successfully implement our cloud-based distribution model; |
|
· |
our ability to develop additional revenue opportunities through new tests, including in the field of cancer diagnostics; |
|
· |
the scope of protection we establish and maintain for intellectual property rights covering Panorama and any other test we may develop; |
|
· |
our estimates regarding our costs and risks associated with our international operations and international expansion; |
|
· |
our ability to retain and recruit key personnel; |
|
· |
our reliance on our direct sales efforts; |
|
· |
our expectations regarding acquisitions and strategic operations; |
|
· |
our ability to fund our working capital requirements; |
|
· |
our compliance with federal, state, and foreign regulatory requirements; |
|
· |
the factors that may impact our financial results; and |
|
· |
anticipated trends and challenges in our business and the markets in which we operate. |